Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Gao, Lina ^a   Schwartzman, Jacob ^a   Gibbs, Angela ^a   Lisac, Robert ^a   Kleinschmidt, Richard ^a   Wilmot, Beth ^b,c   Bottomly, Daniel ^b,c   Coleman, Ilsa ^d   Nelson, Peter ^d   McWeeney, Shannon ^b,c   Alumkal, Joshi ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Oregon Clinic   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; LIGAND; MYC PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; SOFT TISSUE METASTASIS; TRANSCRIPTION REGULATION; UPREGULATION;

ANDROGENS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN; TRIAZOLES; UP-REGULATION;

EID: 84877934286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063563     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Taplin ME, (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4: 236-244.
3. Scher HI, Beer TM, Higano C, Anand A, Taplin M-E, et al. (2010) Antitumour Activity of MDV3100 in a Phase 1-2 Study of Castration-Resistant Prostate Cancer. Lancet 375: 1437-1446.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
5. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, et al. (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30: 637-643.
6. Efstathiou E, Titus MA, Tsavachidou D, Hoang A, Karlou M, Wen S, et al. (2011) MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. J Clin Oncol 29: abstr 4501.
7. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
8. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
9. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
10. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586.
11. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, et al. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804.
12. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M, (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33: 887-894.
13. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
14. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
15. Ueda T, Bruchovsky N, Sadar MD, (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277: 7076-7085.
16. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, et al. (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108: 13728-13733.
17. Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
18. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238.
19. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, et al. (2010) Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13: 311-315.
20. Jenkins RB, Qian J, Lieber MM, Bostwick DG, (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: 524-531.
21. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH, (2003) Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112: 1724-1731.
22. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
23. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 108: 16669-16674.
24. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
25. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
26. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
27. Claassen GF, Hann SR, (2000) A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci U S A 97: 9498-9503.
28. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
29. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, et al. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353.
30. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, et al. (2010) Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116: 1498-1505.
31. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, et al. (2009) miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 35: 610-625.
32. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
33. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, et al. (2010) Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13: 311-315.
34. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med.
35. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, et al. (2006) Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol 26: 8418-8426.
36. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
37. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39-47.
38. Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, et al. (2011) Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther 10: 2309-2319.
39. Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, et al. (2011) Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg Med Chem Lett 21: 5442-5445.
40. Loddick S, Bradbury R, Broadbent N, Campbell H, Gaughan L, et al. (2012) Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer. Cancer Res 72: abstr 3848.
41. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE, (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258.
42. Gibbs A, Schwartzman J, Deng V, Alumkal J, (2009) Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A 106: 16663-16668.
43. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, et al. (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 25: 377-388.
44. True L, Coleman I, Hawley S, Huang CY, Gifford D, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 103: 10991-10996.
45. Mecham BH, Nelson PS, Storey JD, (2010) Supervised normalization of microarrays. Bioinformatics 26: 1308-1315.
46. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, et al. (2011) Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 96: 430-437.